Business Context and Reporting Period
This Form 6-K filing covers the month of March 2017 for BiondVax Pharmaceuticals Ltd. (referred to in the metadata as Scinai Immunotherapeutics Ltd.). The company is a foreign private issuer based in Ness Ziona, Israel, focused on developing vaccine candidates, specifically M-001 for seasonal and pandemic flu strains.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial disclosure relates to a government grant:
- Grant Amount: NIS 4 million (representing 20% of a NIS 20 million budget).
- Grant Purpose: Construction of a manufacturing facility for Phase 3 and commercial batches of product candidate M-001.
- Source: Investment Center of the Ministry of Economy and Industry of the State of Israel.
Material Changes
The material change reported is the receipt of approval for the aforementioned grant on March 28, 2017. This represents a significant non-operating financial event intended to support capital expenditure for manufacturing infrastructure.
Guidance, Outlook, and Conditions
The grant is subject to specific terms and conditions under the Israeli Encouragement of Capital Investment Law, 1959, including:
- Capital Requirement: At least 24% of the investments in the planned facility's fixed assets must be financed by additional share capital.
- Location Restriction: The company must maintain its intellectual property and manufacturing facility in Israel for at least 10 years following receipt of the grant.
The filing incorporates a press release dated March 30, 2017, as Exhibit 99.1 but does not provide further management commentary on financial outlook or risks beyond the grant conditions.
Investor Verification Checklist
- Verify the final disbursement status of the NIS 4 million grant.
- Confirm the company's ability to raise the required additional share capital to meet the 24% fixed asset financing condition.
- Review the attached press release (Exhibit 99.1) for detailed timelines regarding the factory construction.
- Monitor future filings for updates on the M-001 clinical trial progress and manufacturing readiness.